24 results about "New diagnosis" patented technology

The invention discloses intestinal bacteria and serum metabolites which can be used as biomarkers of type 2 diabetes mellitus (prediabetes mellitus (PDM), new diagnosis diabetes mellitus (NDDM) and diabetes mellitus (P2DM) after medication) in different disease stages, and application of the intestinal bacteria and the serum metabolites. Aiming at type 2 diabetes mellitus, predictive markers including staphylococcus aureus, escherichia coli, klebsiella pneumoniae, branched chain amino acids (leucine, valine and isoleucine) and the like, especially staphylococcus aureus of which the genome contains acetolactate synthase (ALS), are efficiently screened out. The type 2 diabetes mellitus marker disclosed by the invention can be used for early warning the illness risk of type 2 diabetes mellitus and guiding the adjustment of an intestinal microbial environment; the method can be used for indicating the correlation between the intestinal microbial environment and the type 2 diabetes mellitus and is used for assisting diagnosis; and drug action target research, accurate medication, pathogenesis research and the like are realized.

The invention provides a spinal health monitoring method and system combining remote sensing three-dimensional modeling and AI pre-diagnosis. The method comprises the following steps: (1) constructing a rapid three-dimensional reconstruction module based on flow diffusion: realizing high-fidelity three-dimensional modeling by adopting a lightweight shape generation and intelligent texture mapping technology; (2) intelligent grading evaluation of scoliosis driven by a large model: based on a large-scale spine feature data set, constructing a deep learning network for automatic measurement and typing prediction of spine parameters, and deeply fusing the deep learning network with a semantic understanding module of an AI intelligent question-answering system; and (3) doctor-worker collaborative diagnosis and feedback optimization: doctors can view the user model and the AI evaluation report and make new diagnosis, meanwhile, the system utilizes natural language processing to extract doctor diagnosis keywords, and the model is continuously optimized based on parameter transfer learning. According to the invention, the whole-process Web deployment of spine detection is realized, a medical vertical domain large model for spine detection is developed, and the extensible technical framework has huge application potential in the field of intelligent medical treatment.

The invention provides application of D-pyroglutamic acid in preparation of a medicine for preventing and / or treating cataract, and belongs to the technical field of medicines. The invention discloses application of D-pyroglutamic acid in preparation of a medicine for preventing and / or treating cataract. Results of the invention show that the D-pyroglutamic acid can effectively inhibit aggregation of crystalline lens proteins. In addition, the D-pyroglutamic acid drug is low in cytotoxicity, directly acts on crystalline epithelial cells and can effectively inhibit damage to the crystalline epithelial cells. Therefore, the medical application of the D-pyroglutamic acid is expanded, and meanwhile, a new diagnosis and treatment strategy is provided for attack and prevention of cataract.

The application relates to the fields of medical diagnosis and gene drugs, and particularly relates to application of long-chain non-coding RNA in preparation of a heart insufficiency diagnosis reagent or kit. The application also provides application of the long-chain non-coding RNA in preparation of a heart insufficiency treatment drug. The application first finds that LOC107984012 is long-chain non-coding RNA which is highly expressed in a failing heart, and provides a new diagnosis marker and treatment target for heart insufficiency.

The invention discloses an electrical design and debugging integrated intelligent platform and an implementation method. Comprising the steps of setting a data model of electrical design debugging; the method comprises the following steps: mapping design data generated based on an electrical logic diagram before debugging to obtain initial debugging data; the simulation model and the physical equipment are connected, a semi-physical simulation environment is constructed, variables of the simulation model and physical signals of the physical equipment are fused during debugging, and debugging data are obtained and updated; performing inverse mapping on the updated debugging data to obtain updated design data, and obtaining an updated electrical logic diagram based on the updated data; and based on the diagnosis knowledge in the data model library, an intelligent diagnosis module is adopted to diagnose the debugging data updated during debugging to obtain new diagnosis data. Design and debugging integration of electrical development is realized, and the intelligent level of fault diagnosis is improved.

The invention belongs to the field of circuit protection, and provides an overcurrent protection monitoring method and system for a frequency converter. The method comprises the following steps: continuously acquiring current time sequence data of three-phase current of each frequency converter in a workstation, sampling to form an original data set, and standardizing the original data set; fault segmentation is carried out on the standardized original data set, so that abnormal data and normal data in the original data set are separated; converting an original data set representing abnormal data from a time domain to a frequency domain based on discrete Fourier transform to obtain a new diagnosis data set; based on a principal component analysis technology, features in the diagnosis data set are extracted and dimensionally reduced to obtain a feature set, the square prediction error of each feature in the feature set is calculated, the total contribution degree of the features is obtained according to the influence of the square prediction error on other features, and whether a detected object fails or not is determined; therefore, the problem that in the prior art, irregular overcurrent faults which do not reach the threshold value are difficult to diagnose can be solved.

The invention belongs to the technical field of biological medicines, and discloses application of L-lactic acid in preparation of a medicine for promoting muscle injury repair and / or regeneration. The L-lactic acid can significantly promote proliferation and differentiation of muscle satellite cells, and helps to improve some external stimulation factors, such as myasthenia, amyotrophy, poor muscle coordination and other skeletal muscle dysfunction diseases caused by aging, injury, disuse or some degenerative diseases, such as poor prognosis. The invention provides a new diagnosis and treatment strategy and an effective molecular treatment target for treatment and prognosis of skeletal muscle dysfunction diseases. And on the other hand, the L-lactic acid provided by the invention is a small molecule metabolite, is relatively low in economic cost and relatively good in treatment effect, and has a considerable clinical application prospect.

The invention discloses a diagnostic marker for the drug resistance of kidney cancer sunitinib. The diagnostic marker for the drug resistance of kidney cancer sunitinib is selected from a group consisting of histone acetyltransferase KAT2A. The invention further discloses a kit for detecting the sunitinib drug resistance of the kidney cancer. The kit comprises a reagent for detecting the expression quantity of KAT2A. The KAT2A provided by the invention is used as a renal cancer sunitinib drug resistance diagnosis marker, has good specificity and high sensitivity, provides a new diagnosis and treatment means for renal cancer sunitinib drug resistance, is beneficial to drug resistance monitoring and avoids further invalid treatment, and has a good medical conversion prospect.

The application discloses a kind of based on HAPLN1 down-regulation induced preeclampsia animal model construction method and application of placental cell abnormal aging, belong to the field of biological medicine technology.The application can stably induce the animal model with typical preeclampsia clinical characteristics by reducing the expression level of HAPLN1 in pregnant mice, while reproducing the abnormal phenotype of placental cell aging.The method has strong controllability in operation process, and the model has good reproducibility, which can provide effective experimental tools for in-depth study of the pathogenesis of preeclampsia and development of new diagnosis and treatment strategies.

The invention belongs to the technical field of biomedicine, and particularly relates to application of a BIRC5 gene in prediction of drug resistance in bladder cancer immunotherapy and in depletion of immune subtypes. The invention is achieved by detecting the expression level of the BIRC5 gene in a tumor sample from a bladder cancer patient, where high expression of BIRC5 indicates that the patient belongs to the depleted immune subtype and predicts drug resistance to immune checkpoint blocking (ICB) treatment. In addition, the invention also discloses an application of the BIRC5 gene as a target spot in screening drugs for reversing tumor immunosuppression microenvironment in bladder cancer or overcoming immunotherapy drug resistance. The invention provides a new biomarker and a therapeutic target for a new depletion immune subtype of bladder cancer, and provides a new diagnosis and treatment strategy for immunotherapy of drug-resistant bladder cancer patients.

Various embodiments of the present invention provide methods, apparatus, systems, computing devices, computing entities, and / or the like for generating a historically dynamic explanation data object for a dental image data object. Certain embodiments of the present invention utilize systems, methods, and computer program products that perform generating a historically dynamic explanation data object for a dental image data object using an encoder-decoder architecture, where the encoder machine learning framework of the encoder-decoder architecture comprises a current diagnosis identification machine learning model, a historical diagnosis identification machine learning model, a convolutional embedding machine learning model, a new diagnosis code inference machine learning model, and a feature vector combination machine learning model.

The invention discloses an oligosaccharide chain fingerprint spectrum prediction model for identifying staphylococcus epidermidis infection and a construction method and application thereof, and belongs to the technical field of molecular biomedicine. The invention discovers that active infection of staphylococcus epidermidis can cause glycoprotein in host serum to generate a characteristic oligosaccharide chain fingerprint spectrum for the first time, and the spectrum can be used as a specific biomarker. Based on the discovery, the invention provides a construction method of a prediction model, which comprises the following steps: acquiring oligosaccharide chain atlas data of a serum sample, training by utilizing a machine learning algorithm, constructing a classifier capable of outputting an infection state prediction value, and determining a judgment threshold for distinguishing infection and negative. By applying the model, the active infection of the staphylococcus epidermidis can be quickly and accurately identified, and sample pollution can be effectively distinguished. The invention provides a brand new diagnosis solution for clinical application, and has important clinical application value.

The application discloses an oncogene VGLL1 and application of a protein coded by the oncogene VGLL1, and particularly discloses application of a VGLL1 gene and / or a coded protein thereof in preparation of a medicine for treating cancer, and application of the VGLL1 gene and / or the coded protein thereof in preparation of a reagent or a kit for cancer diagnosis and / or prognosis judgment. It is found in the application that the oncogene VGLL1 has an important role in the occurrence and development process of tumors, and high expression of VGLL1 can induce malignant progression such as invasion and metastasis of ovarian cancer. It is also found in the research result that conditionally down-regulating VGLL1 can effectively relieve the growth of ovarian cancer cells and inhibit the invasion and metastasis ability of the ovarian cancer cells. The application provides a new diagnosis and treatment idea and a drug screening platform for solving clinical problems such as metastasis of ovarian cancer.

The invention discloses a quality control feedback method and system for electrocardio data and diagnosis results, and the quality control feedback method for the electrocardio data and the diagnosis results comprises three steps. The method has remarkable advantages in the aspect of automatically feeding back and updating the electrocardiogram database, and due to the fact that an existing system mostly depends on manual database maintenance, the updating period is long, response is lagged, newest clinical diagnosis characteristics are difficult to reflect in time, and an effective quality control mechanism is lacked in the data storage process. According to the method, dynamic self-optimization and updating of the database can be realized. According to the method, text analysis and key content extraction are performed on a clinical diagnosis result of an electrocardiogram by using a deep learning model, and similarity matching is performed by combining electrocardiogram characteristics of an object with existing data in a database. And if the matching degree is lower than a set threshold value, the new diagnosis and the features thereof are automatically put in storage, so that real-time learning and continuous expansion are realized. The local database has the adaptive learning capability, and the intelligence and data timeliness of the system are remarkably improved.

The invention discloses application of leucine aminopeptidase in preparation of a product for diagnosing atherosclerosis or evaluating atherosclerotic plaque vulnerability, and discloses direct association between LAP and AS plaque vulnerability and application of LAP as a cardiovascular and cerebrovascular disease diagnosis biomarker for the first time. The invention relates to application of the LAP activity in preparation of a product for diagnosing AS or evaluating AS plaque vulnerability, further provides a first method for in-vivo, real-time and dynamic visual imaging of the LAP activity in a living body AS plaque, in addition, the feasibility of diagnosing AS based on the LAP activity is verified in various human source clinical samples for the first time, the perfect distinction degree is achieved, and finally, the application of the LAP activity in preparation of a product for diagnosing AS or evaluating AS plaque vulnerability is achieved. A complete evidence chain is formed through multi-modal means such as in-vivo imaging, in-vitro imaging and histopathology; the method has the advantages that a brand new diagnosis and research direction is opened up for AS diagnosis or AS plaque vulnerability evaluation, the LAP activity in the AS plaque can be specifically identified and imaged and displayed in a living body environment, and a more accurate and timely disease monitoring means is provided.

The invention provides application of a novel biomarker sKLB of sepsis intestinal mucous barrier damage in detection, diagnosis and treatment of sepsis. Clinical sample exploration proves that the sKLB has good correlation with sepsis in people, so that a new diagnosis and treatment marker is provided for clinical diagnosis and treatment of sepsis, and the application has important clinical significance.

The invention belongs to the technical field of diabetes diagnosis, and particularly relates to application of a reagent for detecting intestinal microorganisms and excrement metabolites in preparation of a preparation for diagnosing diabetes and a kit. Key biomarkers including key differential intestinal microorganisms and key differential fecal metabolites are screened through metagenomics and metabonomics, and the clinical value of the key biomarkers lies in that a multi-omics classifier for distinguishing adult illness T1D from healthy people (HC) and T2D is finally determined. The kit is helpful for accurate diagnosis and typing of adult onset T1D and provides a brand new diagnosis and treatment target for the adult onset T1D.

The invention relates to the technical field of biological medicines, in particular to application of MiR-30e-5p in diagnosis and treatment of pulmonary arterial hypertension of broilers. A chick embryo hypoxia model and a PASMCs hypoxia model are constructed, the effects of miR-30e-5p on proliferation, migration and phenotypic transformation of PASMCs are systematically researched, and the result shows that the expression of miR-30e-5p can be up-regulated by hypoxia, the proliferation, migration activity and phenotypic transformation capacity of hypoxia-induced PASMCs can be remarkably reduced by knocking down miR-30e-5p in vivo and in vitro, pulmonary artery remodeling is inhibited, and the hypoxia-induced PASMCs can be used for treating pulmonary artery remodeling. A new diagnosis and treatment target is provided for effectively preventing and treating the pulmonary hypertension of the broilers, and a new thought is provided for diagnosis and treatment target screening and drug research and development of the pulmonary hypertension of the broilers.

The application provides an electrochemical immunosensor for detecting mycobacterium tuberculosis antigen ESAT-6. 60 The application prepares a composite material MXene / C 60 NPs / Au@Pt, and a large number of ESAT-6 aptamers Apt2 are loaded through the bonding of metal particles and amino groups, and finally form a MXene / C 60 NPs / Au@Pt / Apt2 signal probe solution, which effectively amplifies the electrochemical signal. The introduction of gold nanoparticle loaded MoS2 (MoS2-AuNPs) can promote electron transfer, and the density of ESAT-6 aptamer Apt1 on the electrode is increased by using the biotin avidin system, and a novel electrochemical aptamer biosensor based on double signal output is successfully constructed for the detection of ESAT-6 in a typical sandwich form, which provides a new diagnosis approach for the early diagnosis of tuberculosis patients.

The invention discloses a multi-dimensional performance point number measuring and calculating method, which belongs to the technical field of medical quality management, and comprises the following steps: 1) constructing a medical four-dimensional index system: presetting four dimensions of clinical quality, patient safety, operation efficiency and scientific research and innovation, integrating DRG grouping and JCI standard related indexes, and when a new diagnosis and treatment project is added, establishing a medical four-dimensional index system; automatically associating exclusive indexes through clinical path mapping; 2) three-drive weight dynamic adjustment: strategic drive: adjusting strategic key dimension weight through a management end interface; according to the method, medical special indexes such as a DRG-CM I value and D-to-B time are brought into performance, 12 JCI core standard indexes are covered, a weight fusing mechanism realizes medical insurance compliance one-ticket override, compared with a traditional method, the response speed is increased by 70%, the problem that workloads of different departments are incomparable is solved through a case difficulty coefficient, hyper-branched cases are automatically traced through medical insurance-performance linkage, and the efficiency of medical insurance-performance linkage is improved. After implementation in a certain hospital, the medical insurance refusing rate is reduced by 32%, and a doctor can master personal / department / whole hospital three-level performance ranking in real time through early warning of the mobile terminal.

The invention belongs to the technical field of diabetes diagnosis, and particularly relates to application of a reagent for detecting excrement metabolites in preparation of a preparation for diagnosing diabetes and a kit. Key biomarkers including key differential intestinal microorganisms and key differential fecal metabolites are screened through metagenomics and metabonomics, and the clinical value of the key biomarkers lies in that a multi-omics classifier for distinguishing adult illness T1D from healthy people (HC) and T2D is finally determined. The kit is helpful for accurate diagnosis and typing of adult onset T1D and provides a brand new diagnosis and treatment target for the adult onset T1D.

The application discloses an incremental meta-learning online fault diagnosis method for industrial streaming data, and comprises the following steps: S1: collecting vibration signals of different fault modes under different working conditions through a sensor, and dividing a plurality of diagnosis stage data sets; S2: building and training an initial fault diagnosis model; S3: introducing a Herding algorithm to select a small batch of representative samples from an old task training data set and store the samples in a data cache module; S4: jointly and randomly sampling a multi-task training set from the data cache module and a new stage training data set, and updating parameters of each sub-task model through meta-training; and S5: updating general model parameters through a dynamic balance meta-updating strategy. The method can mine general diagnosis knowledge among tasks of different stages, and through the design of a dynamic meta-updating strategy, learning of new knowledge and memory of old knowledge of the model can be balanced, so that the model can be quickly generalized to new diagnosis tasks, new fault data and new fault modes.

The invention provides application of a circular RNA molecule circ-PHF21A in preparation of a diagnostic kit and a drug for glioblastoma, and the diagnostic kit and the drug of the circular RNA molecule circ-PHF21A. According to the application disclosed by the invention, low expression of circ-PHF21A in a glioblastoma tissue is found through a bioinformatics method, and malignant biological behaviors of glioblastoma are inhibited through overexpression of circ-PHF21A. Meanwhile, the circular RNA is found to be capable of coding functional protein so as to play a tumor inhibition role. Therefore, the circ-PHF21A can be used as a molecular marker for malignant progression of the glioblastoma, and a new diagnosis and treatment strategy is provided for treatment of the glioblastoma.

The invention discloses an application of keratin sulfate in diagnosis of chronic periodontitis, and relates to the technical field of biological medicines, and the technical key points are as follows: a detection kit taking keratin sulfate as a molecular marker, a keratin sulfate monoclonal antibody and a human keratin sulfate (KS) enzyme-linked immunosorbent assay kit are utilized, and the application of keratin sulfate in diagnosis of chronic periodontitis is realized. According to the method, the expression level of keratin sulfate in gingival crevicular fluid is detected, clinical diagnosis of chronic periodontitis is assisted, a novel diagnosis and treatment strategy is provided for chronic periodontitis patients with increased keratin sulfate level, and a diagnostic technical foundation is laid for realizing long-acting management of chronic periodontitis by combining a targeted keratin sulfate therapy.